No photo of Rasmus Bisbjerg

Rasmus Bisbjerg


    Research activity per year

    If you made any changes in Pure these will be visible here soon.

    Personal profile


    Prostate cancer

    Main research areas

    Mainly company-sponsored research

    Current research


    FASE II: A phase 2, open-label, single-arm, efficacy, and safety study of an investigational (Enzalutamide) drug in patients with hormone-naïve prostate cancer - now open-label

    Role: Principal Investigator


    PRIMORDIUM (2021-): A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients

    Role: Principal Investigator


    DAROL (2022-): Darolutamide Observational Study in nonmetastatic castration-resistant prostate cancer patients

    Role: Principal Investigator




    BraVac: A Phase 2, Double-Blind, Placebo-Controlled Study of RV001V in Men with Biochemical Failure following Curatively Intended Therapy for Localized Prostate Cancer

    Role: Sub-Investigator


    PROSPER: A multinational, phase 3, randomized, double-blind, placebo-controlled efficacy and safety study of an investigational drug in patients with non-metastatic castration-resistant prostate cancer.

    Role: Sub- Investigator and Principal Investigator


    ARCHES: A multinational, phase 3, randomized, double-blinded, placebo-controlled efficacy and safety study of an investigational drug plus Androgen Deprivation Therapy versus placebo + Androgen Deprivation Therapy in patients with metastatic hormone-sensitive prostate cancer

    Role: Sub-Investigator


    TERRAIN: A randomized, double-blind, phase 2, efficacy and safety study of an investigational drug versus Bicalutamide in castrate men with metastatic prostate cancer – open-label after.

    Role: Sub-Investigator


    CORAL: A randomized, multi-site, double-blinded, double-dummy, active control, parallel-group, multidose, efficacy, safety, and tolerability phase 3 study of an oral investigational drug versus Morphine in subjects with chronic moderate to severe pain related to cancer

    Role: Sub-Investigator


    OREXO: A phase 2, randomized, double-blind, placebo-controlled, dose-finding trial using a sublingual investigational drug to alleviate pain associated with a prostate biopsy procedure

    Role: Sub-Investigator


    GALAHAD: A phase 2 efficacy and safety study of an investigational drug in men with metastatic castration-resistant prostate cancer with DNA-repair anomalies.

    Role: Principal Investigator


    PREVAIL: A multinational, double-blind, randomized, placebo-controlled phase 3 trial of an investigational drug + GnRH therapy in chemotherapy-naïve patients with progressive metastatic CRPC who have failed ADT - now open-label

    Role: Sub-Investigator


    PROSPECT/PROSTVAC: A randomized, double-blind, phase 3 efficacy trial of an investigational vaccine in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer

    Role: Sub-Investigator


    FERRING:  A prospective observational safety study in patients with advanced prostate cancer treated with a GnRH antagonist or a GnRH agonist

    Role: Sub-Investigator


    HERO: A multinational phase 3, randomized, open-label, parallel Group study to evaluate the safety and efficacy of an investigational drug in men with advanced prostate cancer

    Role: Principal Investigator


    PREMISE: A European prospective observational study assessing the efficacy and outcomes associated with AR-targeted treatment in patients with metastatic castration-resistant prostate cancer.

    Role: Sub-Investigator

    Potential conflicts of interest

    Advisory board member for the “Danish Medicines Council” regarding Prostate cancer (2020 - )


    Dive into the research topics where Rasmus Bisbjerg is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
    • 1 Similar Profiles


    Recent external collaboration on country/territory level. Dive into details by clicking on the dots or